Variability in donor-specific alloantibody production after transplantation

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• The role of de novo donor-specific alloantibodies (DSAs) in renal allograft injury remains incompletely understood.
• Assessing DSA development and its impact on graft function is critical for improving transplant outcomes.

Purpose of the Study:

• To evaluate the incidence and timing of de novo DSA development post-kidney transplantation.
• To identify the causes of DSA production.
• To determine the association between DSAs and renal allograft function and rejection.

Main Methods:

• Prospective study of 78 kidney transplant recipients with negative pre-transplant cross-matches.
• Serial serum sampling for DSA detection using complement-dependent lymphocytotoxic (CDC) cross-match assays at multiple time points up to 12 months post-transplant.
• Correlation of DSA occurrence with acute rejection episodes and C4d deposition, and assessment of serum creatinine levels.

Main Results:

• De novo DSAs developed in 44.8% of recipients within the first year, with the highest incidence in the first month.
• DSA appearance was associated with acute rejection in 57.1% of cases, and C4d deposition was noted in 11 patients.
• Patients with DSAs exhibited significantly higher serum creatinine levels, indicating poorer renal allograft function compared to those without DSAs.

Conclusions:

• Kidney transplant recipients frequently develop de novo donor-specific alloantibodies, particularly within the first month post-transplant.
• The presence of DSAs is strongly linked to acute rejection episodes and contributes to impaired long-term renal allograft function.
• Monitoring for DSAs is essential for identifying patients at risk of graft injury and optimizing post-transplant management.